1st Quarter Fiscal 2026 Earnings Presentation November 6, 2025 | We shop. You save. Disclaimer Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "could," "predict," "potential," "believe," "will likely result," "expect," "continu ...

Financial Performance - Consolidated revenue for Q1 FY 2026 was $328.8 million, up from $292.3 million in Q1 FY 2025, representing a 12.5% increase[1] - Consolidated net loss for Q1 FY 2026 was $30.5 million, an improvement from a net loss of $44.5 million in Q1 FY 2025[1] - Adjusted EBITDA for Q1 FY 2026 was $(32.1) million, compared to $(1.7) million in Q1 FY 2025[1] - The net loss attributable to common shareholders for the quarter was $47.9 million, compared to a net loss of $44.5 million in the same quarter last year[38] - Net loss for Q3 2025 was $30,459,000, a decrease from a net loss of $44,546,000 in Q3 2024, representing a 31.6% improvement[45] - Total revenue from reportable segments in Q3 2025 was $326,994,000, compared to $287,937,000 in Q3 2024, reflecting a 13.6% increase[41] - Adjusted EBITDA for Q3 2025 was $(32,079,000), compared to $(1,683,000) in Q3 2024, indicating a significant decline in profitability[45] Segment Performance - The Senior segment reported revenue of $59.0 million, down 37% from $92.9 million in the same period last year[6] - The Healthcare Services segment generated revenue of $221.4 million, a 42% increase from $155.7 million in Q1 FY 2025[14] - The Life segment reported revenue of $46.6 million, a 19% increase from $39.3 million in Q1 FY 2025[23] - Pharmacy revenue reached $218.5 million, up 43% from $152.9 million year-over-year[38] - Adjusted Segment EBITDA for Healthcare in Q3 2025 was $7,212,000, down from $7,724,000 in Q3 2024, a decrease of 6.6%[41] Customer Metrics - The number of SelectRx members increased by 24% year-over-year, reaching 106,914 members as of September 30, 2025[16] - The revenue to customer acquisition cost (CAC) ratio reached an all-time high of 6.4x, nearly 40% higher than the previous year[2] - Approved Medicare Advantage policies decreased by 32% to 62,510 in Q1 FY 2026 from 91,680 in Q1 FY 2025[11] Financial Outlook - The company maintains its fiscal 2026 financial outlook of $1.65 to $1.75 billion in revenue and $120 to $150 million in Adjusted EBITDA[4] Cash Flow and Assets - Cash used in operating activities for Q3 2025 was $21,623,000, compared to $16,610,000 in Q3 2024, showing an increase in cash outflow[45] - Cash and cash equivalents at the end of Q3 2025 were $15,699,000, down from $42,690,000 at the beginning of the period[45] - Total current assets decreased to $332.0 million from $341.0 million as of June 30, 2025[36] - Total liabilities as of September 30, 2025, were $660.1 million, a decrease from $673.8 million as of June 30, 2025[37] - Commissions receivable-current increased to $193.4 million from $132.1 million, indicating growth in expected revenue[36] Business Structure - The company has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life, focusing on various insurance and healthcare services[33] Other Financial Metrics - The company reported a loss from operations of $40.7 million for the quarter, compared to a loss of $12.0 million in the prior year[38] - SelectQuote's accumulated deficit increased to $252.6 million as of September 30, 2025, from $222.2 million as of June 30, 2025[37] - Proceeds from the revolving credit facility in Q3 2025 were $80,000,000, with payments of $65,000,000, resulting in a net increase of $15,000,000[45] - Total cash used in investing activities for Q3 2025 was $3,984,000, an increase from $2,574,000 in Q3 2024[45] - The company reported a change in fair value of warrants of $(15,036,000) in Q3 2025, compared to no such change in Q3 2024[45]

Core Viewpoint - A lawsuit has been filed against SelectQuote, Inc. for alleged violations of securities laws, claiming misleading statements and undisclosed practices related to Medicare beneficiaries [2]. Group 1: Lawsuit Details - The lawsuit was initiated by an investor who purchased shares of SelectQuote, Inc. (NYSE: SLQT) prior to September 2020 [1]. - Allegations include that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of the quality of the plans [2]. - The company is accused of not providing unbiased comparisons for Medicare Advantage insurance plans and receiving illegal kickbacks [2]. - As a result of these practices, SelectQuote is said to be vulnerable to regulatory and legal sanctions, including potential violations of the False Claims Act [2]. Group 2: Investor Information - Investors who purchased shares of SelectQuote, Inc. are encouraged to contact the Shareholders Foundation for further information and options [1][3].

Core Points - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. and reminds investors of the October 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2][3] Allegations Against SelectQuote - The complaint alleges that SelectQuote and its executives violated federal securities laws by making false and misleading statements, including directing Medicare beneficiaries to plans that compensated SelectQuote the most, rather than providing unbiased comparisons [4] - SelectQuote is accused of receiving illegal kickbacks from health insurance companies to steer Medicare beneficiaries towards certain plans, which led to non-compliance with applicable laws and regulations [4][5] - The U.S. Department of Justice filed a complaint against SelectQuote, alleging that from 2016 to at least 2021, the company received tens of millions of dollars in illegal kickbacks and engaged in discriminatory practices against less profitable beneficiaries [5] Stock Market Reaction - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually heavy trading volume [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, of the lead plaintiff deadline on October 10, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought SelectQuote securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 10, 2025 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements and failed to disclose critical information regarding its business practices [4] - Specific allegations include directing Medicare beneficiaries to insurers that compensated SelectQuote, not providing unbiased comparisons for Medicare Advantage plans, and receiving illegal kickbacks [4] - The lawsuit claims that these actions made SelectQuote vulnerable to regulatory and legal sanctions, including potential violations of the False Claims Act [4]

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for allegedly receiving illegal kickbacks from health insurance companies and misleading investors about its business practices [5]. Allegation Details - The U.S. Department of Justice filed a complaint against SelectQuote, alleging that from 2016 to at least 2021, the company received "tens of millions of dollars" in illegal kickbacks for steering Medicare beneficiaries to specific insurance plans [5]. - The lawsuit claims that SelectQuote made materially false statements regarding its services, asserting it provided unbiased coverage comparisons while actually directing beneficiaries to the most profitable plans for the company [5]. Stock Impact - Following the DOJ's announcement, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually high trading volume [5]. Legal Process - Investors who purchased SelectQuote securities between September 9, 2020, and May 1, 2025, have until October 10, 2025, to apply to be appointed as lead plaintiff in the lawsuit [5].

Core Viewpoint - SelectQuote Inc. is under increased legal scrutiny following a whistleblower lawsuit alleging deceptive sales practices, leading to a significant drop in its stock price and a subsequent class-action lawsuit from investors [1][4]. Legal Issues - The U.S. Department of Justice (DOJ) has intervened in a whistleblower lawsuit against SelectQuote, which claims the company engaged in misleading sales practices related to Medicare Advantage plans [1][3]. - The lawsuit, Pahlkotter v. SelectQuote Inc. et al., includes investors who purchased shares between September 9, 2020, and May 1, 2025, alleging that SelectQuote misrepresented its business model and regulatory risks [2][5]. Allegations of Misconduct - The complaint alleges that SelectQuote misrepresented its sales practices, claiming to provide "unbiased advice" while actually directing customers towards higher-commission plans and accepting illegal kickbacks [3][7]. - The DOJ's complaint indicates that from 2016 to at least 2021, SelectQuote received tens of millions of dollars in improper payments and discriminated against less profitable customers [3][7]. Market Reaction - Following the DOJ's involvement, SelectQuote's stock price fell nearly 20% in a single day, and shares have declined over 40% in the past six months due to investor concerns about legal exposure and reputational damage [4][5]. Investigative Actions - Hagens Berman, a shareholder rights firm, is investigating whether SelectQuote's revenue was artificially inflated through deceptive practices, transforming the situation into a serious federal matter [6].

Core Viewpoint - SelectQuote Inc. is under increased legal scrutiny due to a whistleblower lawsuit alleging deceptive sales practices, leading to a significant drop in its stock price and a subsequent class-action lawsuit from investors [1][5][6] Legal Issues - The U.S. Department of Justice (DOJ) has intervened in a lawsuit claiming SelectQuote engaged in misleading sales practices related to Medicare Advantage plans, resulting in improper payments and discrimination against less profitable customers [4][8] - The class-action lawsuit, Pahlkotter v. SelectQuote Inc. et al., includes investors who purchased shares between September 9, 2020, and May 1, 2025, alleging that the company misrepresented its business model and regulatory risks [2][6] Market Impact - Following the DOJ's involvement, SelectQuote's stock price fell nearly 20% on May 1, 2025, and has since declined over 40% in the past six months, reflecting investor concerns about legal exposure and reputational damage [5][6] Allegations of Misconduct - The lawsuit claims SelectQuote misrepresented its services as providing unbiased advice while allegedly steering customers towards higher-commission plans and accepting illegal kickbacks [4][8] - The DOJ's complaint indicates that SelectQuote's actions may have violated federal statutes, including the False Claims Act [8]

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for allegedly receiving illegal kickbacks from health insurance companies and misleading investors about its business practices [6]. Allegation Details - The U.S. Department of Justice filed a complaint against SelectQuote, alleging that from 2016 to at least 2021, the company received "tens of millions of dollars" in illegal kickbacks for steering Medicare beneficiaries to specific insurance plans [6]. - The lawsuit claims that SelectQuote made materially false statements regarding its services, asserting it provided unbiased coverage comparisons while actually directing beneficiaries to the most profitable plans for the company [6]. - Specific allegations include failure to disclose that SelectQuote did not provide unbiased comparisons, received illegal kickbacks, and was vulnerable to regulatory sanctions [6]. Stock Impact - Following the DOJ's announcement, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually high trading volume [6]. Next Steps - Investors who purchased SelectQuote shares between September 9, 2020, and May 1, 2025, and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][6]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 10, 2025 [6].

Group 1 - A shareholder has filed a class action lawsuit against SelectQuote, Inc. (NYSE: SLQT) on behalf of purchasers and acquirers of its securities during the class period from September 9, 2020, to May 1, 2025 [1] - SelectQuote operates as an insurance broker [1] - The Rosen Law Firm is investigating the allegations related to the lawsuit [1]